scholarly journals Epidemic Characteristics of Carbapenem-Resistant Klebsiella pneumoniae in the Pediatric Intensive Care Unit of Yanbian University Hospital, China

2020 ◽  
Vol Volume 13 ◽  
pp. 1439-1446
Author(s):  
Chunmei Jin ◽  
Rong Shi ◽  
Xue Jiang ◽  
Fuxian Zhou ◽  
Jixiang Qiang ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Klebsiella Pneumoniae ◽  
Pediatric Intensive Care Unit ◽  
Pediatric Intensive Care ◽  
University Hospital ◽  
Carbapenem Resistant

Study of fungal infections in pediatric intensive care unit in Menoufiya University Hospital

2014 ◽  
Vol 27 (1) ◽  
pp. 55
Author(s):  
NagwanY. Saleh ◽  
FadyM. ElGendy ◽  
FahimaM. Hassan ◽  
AhmedA. Khatab ◽  
GhadaR. El-Hendawy
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Pediatric Intensive Care Unit ◽  
Fungal Infections ◽  
Pediatric Intensive Care ◽  
University Hospital

scholarly journals Efficacy and safety of dexmedetomidine for prevention of withdrawal syndrome in the pediatric intensive care unit: protocol for an adaptive, multicenter, randomized, double-blind, placebo-controlled, non-profit clinical trial

Trials ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Maria Cristina Mondardini ◽  
Francesca Sperotto ◽  
Marco Daverio ◽  
Fabio Caramelli ◽  
Dario Gregori ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Pediatric Intensive Care Unit ◽  
Withdrawal Syndrome ◽  
Clinical Signs ◽  
Pediatric Intensive Care ◽  
University Hospital ◽  
Prolonged Treatment ◽  
Double Blind ◽  
Double Blind Placebo

Abstract Background Prolonged treatment with analgesic and sedative drugs in the pediatric intensive care unit (PICU) may lead to undesirable effects such as dependence and tolerance. Moreover, during analgosedation weaning, patients may develop clinical signs of withdrawal, known as withdrawal syndrome (WS). Some studies indicate that dexmedetomidine, a selective α2-adrenoceptor agonist, may be useful to prevent WS, but no clear evidence supports these data. The aims of the present study are to evaluate the efficacy of dexmedetomidine in reducing the occurrence of WS during analgosedation weaning, and to clearly assess its safety. Methods We will perform an adaptive, multicenter, randomized, double-blind, placebo-controlled trial. Patients aged < 18 years receiving continuous intravenous analgosedation treatment for at least 5 days and presenting with clinical conditions that allow analgosedation weaning will be randomly assigned to treatment A (dexmedetomidine) or treatment B (placebo). The treatment will be started 24 h before the analgosedation weaning at 0.4 μg/kg/h, increased by 0.2 μg/kg/h per hour up to 0.8 μg/kg/h (neonate: 0.2 μg/kg/h, increased by 0.1 μg/kg/h per hour up to 0.4 μg/kg/h) and continued throughout the whole weaning time. The primary endpoint is the efficacy of the treatment, defined by the reduction in the WS rate among patients treated with dexmedetomidine compared with patients treated with placebo. Safety will be assessed by collecting any potentially related adverse event. The sample size assuring a power of 90% is 77 patients for each group (total N = 154 patients). The study was approved by the Ethics Committee of the University-Hospital S.Orsola-Malpighi of Bologna on 22 March 2017. Discussion The present trial will allow us to clearly assess the efficacy of dexmedetomidine in reducing the occurrence of WS during weaning from analgosedation drugs. In addition, the study will provide a unique insight into the safety profile of dexmedetomidine. Trial registration ClinicalTrials.gov, NCT03645603. Registered on 24 August 2018. EudraCT, 2015–002114-80. Retrospectively registered on 2 January 2019.

scholarly journals Pola Kuman dan Uji Kepekaan Antibiotik pada Pasien Unit Perawatan Intensif Anak RSMH Palembang

Sari Pediatri ◽  
2016 ◽  
Vol 12 (1) ◽  
pp. 1
Author(s):  
Afriyan Wahyudhi ◽  
Silvia Triratna
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Klebsiella Pneumoniae ◽  
Pediatric Intensive Care Unit ◽  
Pediatric Intensive Care ◽  
Acinetobacter Calcoaceticus ◽  
Staphylococcus Spp

Latar belakang. Unit perawatan intensif anak atau Pediatric Intensive Care Unit (PICU) termasuk unit denganbanyak pemakaian antibiotik. Pemilihan awal antibiotik secara empiris, selanjutnya memerlukan data jeniskuman serta resistensinya terhadap antibiotik. Pemakaian antibiotik yang tidak tepat akan mengakibatkanresistensi kuman dan memperburuk kondisi pasien kritis.Tujuan. Mengetahui pola kuman dan uji kepekaan pasien baru yang dirawat di Unit Perawatan Intensifsebagai salah satu dasar untuk menentukan terapi empiris.Metode. Studi deskriptif pada serial kasus pasien yang dirawat di Unit Perawatan Intensif (PICU) AnakRSMH/FK UNSRI Palembang sejak April 2009 sampai dengan September 2009. Data dianalisis secaradeskriptif dengan tampilan frekuensi dan persentase menggunakan program SPSS 15.0.Hasil. Subjek penelitian 69 orang berusia antara 1 bulan sampai 15 tahun, 58% laki-laki dan 42%perempuan. Ditemukan 75,4% pasien baru terdapat kuman dalam spesimen cairan tubuhnya. Infeksiterbanyak adalah bronkopneumonia (21%). Saluran napas merupakan lokasi terbanyak terdapat bakteri(93,9%), diikuti dengan darah (33,3%), terakhir adalah urin (29%). Bakteri terbanyak yang ditemukan daripemeriksaan biakan adalah Staphylococcus spp. (22,97%), Acinetobacter calcoaceticus (21,62%), Pseudomonasaeruginosa (13,51%), Klebsiella pneumoniae (12,16%), Streptococcus spp. (9,45%), dan sisanya 20,56%mikroorganisme lain. Imipenem dan amikacin masih memiliki sensitifitas yang tinggi terhadap seluruhbakteri yang ditemukan. Antibiotik seperti ceftriaxon, ampicillin, dan gentamicin menunjukkan resistensiyang cukup tinggi. Vancomicin memiliki efektifitas yang sangat baik dan memiliki sensitifitas 100% untuksemua sampel yang diuji.Kesimpulan. Bakteri terbanyak yang ditemukan adalah Staphylococcus, sedangkan imipenem, amikacin,dan vancomicin memiliki sensitifitas yang tinggi terhadap seluruh bakteri yang ditemukan.

scholarly journals Efficacy and safety of Dexmedetomidine for prevention of withdrawal syndrome in Pediatric Intensive Care Unit: protocol for an adaptive, multicenter, randomized, double blind, placebo-controlled, non-profit clinical trial

2019 ◽  
Author(s):  
Maria Cristina Mondardini ◽  
Francesca Sperotto ◽  
Marco Daverio ◽  
Fabio Caramelli ◽  
Dario Gregori ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Pediatric Intensive Care Unit ◽  
Withdrawal Syndrome ◽  
Clinical Signs ◽  
Pediatric Intensive Care ◽  
University Hospital ◽  
Prolonged Treatment ◽  
Double Blind ◽  
Double Blind Placebo

Abstract Background: Prolonged treatment with analgesic and sedative drugs in Pediatric Intensive Care Unit (PICU) may lead to undesirable effects as dependence and tolerance. Moreover, during the analgosedation weaning patients may develop clinical signs of withdrawal, known as withdrawal syndrome (WS). Some studies indicated that dexmedetomidine, a selective α2-adrenoceptors agonist, may be useful to prevent WS, but no clear evidences support this data. Aims of the present study are to evaluate the efficacy of dexmedetomidine in reducing the occurrence of WS during the analgosedation weaning, and to clearly assess its safety. Methods: We will perform an adaptive, multicenter, randomized, double-blind, placebo-controlled trial. Patients <18 years receiving a continuous intravenous analgosedation treatment for at least 5 days and presenting with clinical conditions that allows the analgosedation weaning will be randomly assigned to treatment A (dexmedetomidine) or treatment B (placebo). The treatment will be started 24 hours before the analgosedation-weaning at 0.4 mcg/kg/h, increased of 0.2 mcg/kg/h per hour up to 0.8 mcg/Kg/h (neonate: 0.2 mcg/Kg/h, increased of 0.1 mcg/Kg/h per hour up to 0.4 mcg/Kg/h)and continued throughout the whole weaning-time. The primary endpoint is the efficacy of the treatment, defined by the reduction in WS rate among patients treated with dexmedetomidine comparing with patients treated with placebo. Safety will be assessed collecting any potentially-related adverse event. The sample size assuring a power of 90% is 77 patients for each group (N total=154 patients). The study was approved by the Ethics Committee of the University-Hospital S.Orsola-Malpighi of Bologna on 22 March 2017. Discussion: The present trial will allow to clearly assess the efficacy of dexmedetomidine in reducing the occurrence of WS during the weaning of analgosedation drugs. In addition, the study will provide a unique insight into the safety profile of dexmedetomidine. Trial registration: AIFA ID TIP-15-01.ClinicalTrials.govID NCT03645603, registered on 24 August 2018. Retrospectively registered on EudraCT with ID 2015-002114-80 on 2 Jan 2019.

Sign in / Sign up

Export Citation Format

Share Document